A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)

Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
12/2001
12/04/2001	US6326507 Therapeutic compounds and methods of use
12/04/2001	US6326500 Imidazole derivatives for blocking the release of arachidonic acid from phospholipids
12/04/2001	US6326492 Heterocyclic protease inhibitors
12/04/2001	US6326403 Cardiovascular disorders
12/04/2001	US6326388 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
12/04/2001	US6326385 Administering poltassium channel modulator
12/04/2001	US6326359 Adenosine A2A receptor agonists as antiinflammatory agents
12/04/2001	US6326353 123therapy for septic shock; administering polymyxin by injection
12/04/2001	US6326162 Assays and peptide substrate for determining aggrecan degrading metallo protease activity
12/04/2001	US6326027 Solid, oral dosage form, comprising tramadol or its salt in matrix providing at least twelve hour effectiveness
12/04/2001	US6326008 Toxoplasma gondii antigens, the preparation thereof and the use thereof
12/04/2001	US6325999 Use of Fas ligand to suppress T-lymphocyte-mediated immune responses
12/04/2001	CA2208836C Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
12/04/2001	CA2139948C Targeting somatic gene therapy to joints
12/04/2001	CA1341324C Esterase enzymes used in the process for the preparation of 2-arylpropionic acids
11/2001
11/29/2001	WO2001090361A2 Modulation of inflammation by protease-treated mcp-3 chemokine
11/29/2001	WO2001090359A2 G-protein coupled receptors
11/29/2001	WO2001090334A2 Drug metabolizing enzymes
11/29/2001	WO2001090330A2 AMINOACYL tRNA SYNTHETASES
11/29/2001	WO2001090189A2 G-protein coupled receptor org3.
11/29/2001	WO2001090186A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
11/29/2001	WO2001090156A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use
11/29/2001	WO2001090129A2 Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
11/29/2001	WO2001090110A1 Macrolides
11/29/2001	WO2001090106A2 Tryasolyl tropane derivatives as ccr5 modulators
11/29/2001	WO2001090104A2 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
11/29/2001	WO2001090103A2 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
11/29/2001	WO2001090101A1 Arylmethylamine derivatives for use as tryptase inhibitors
11/29/2001	WO2001090100A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
11/29/2001	WO2001090095A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
11/29/2001	WO2001090094A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090093A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090092A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090091A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090090A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/29/2001	WO2001090086A1 A polymorph of 5-(4-aminosulfonyl-3-fluorophenyl)-4-cyclohexyl-2-methyloxazole
11/29/2001	WO2001090083A1 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
11/29/2001	WO2001090076A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
11/29/2001	WO2001090074A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)
11/29/2001	WO2001090070A2 Caspase inhibitors and uses thereof
11/29/2001	WO2001090068A2 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
11/29/2001	WO2001090063A2 Prodrug of an ice inhibitor
11/29/2001	WO2001090051A1 Phenylglycine derivatives
11/29/2001	WO2001090047A1 Novel mmp-2/mmp-9 inhibitors
11/29/2001	WO2001089616A1 Aerosol container for formulations of salmeterol xinafoate
11/29/2001	WO2001089552A1 Modulaton of alpha-6 integrin-mediated responses
11/29/2001	WO2001089549A2 Therapeutic uses of il-1 receptor antagonist
11/29/2001	WO2001089547A1 Antioxidant and skin preparations for external use
11/29/2001	WO2001089544A1 Antimigraine combination comprising sapindus and emblica extracts
11/29/2001	WO2001089542A2 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/29/2001	WO2001089536A2 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
11/29/2001	WO2001089531A1 Crystal structures of p- selectin,ep0105895-selectin complexes, and uses thereof
11/29/2001	WO2001089526A1 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
11/29/2001	WO2001089520A2 Dehydroascorbic acid formulations and uses thereof
11/29/2001	WO2001089515A1 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
11/29/2001	WO2001089504A1 Tropolone derivatives and pharmaceutical compositions
11/29/2001	WO2001089502A2 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
11/29/2001	WO2001089485A1 Rapidly disintegrating tablet and process for the manufacture thereof
11/29/2001	WO2001089469A1 Topical composition containing at least one aryl oxime, and method for the preparation thereof
11/29/2001	WO2001089467A1 Composition containing at least one aryl oxime and at least one active substance for treating acne and the use thereof
11/29/2001	WO2001089451A2 Protease inhibitors
11/29/2001	WO2001089319A2 Tryptophan source from plants and uses therefor
11/29/2001	WO2001070695A8 Pyridine derivatives as inhibitors of p38
11/29/2001	WO2001060835A8 Purine derivatives
11/29/2001	WO2001055115A8 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/29/2001	WO2001049305A3 Process for obtaining thylakoids from plants, pure thylakoids and use thereof
11/29/2001	WO2001044465A3 Therapeutically useful synthetic oligonucleotides
11/29/2001	WO2001042471A8 Polypeptides and polynucleotides encoding same
11/29/2001	WO2001038566A3 Screening method for candidate drugs
11/29/2001	WO2000055159A3 Substituted aza-oxindole derivatives
11/29/2001	WO2000047104A9 Antagonists of hmg1 for treating inflammatory conditions
11/29/2001	WO2000039114A3 Substituted oximes and hydrazones as neurokinin antagonists
11/29/2001	WO2000010548A3 19-nor-vitamin d3 compounds with calcemic activity
11/29/2001	US20010047090 VANILREP1 polynucleotides and VANILREP1 polypeptides
11/29/2001	US20010047019 3-Aminopyrazole inhibitors of cyclin dependent kinases
11/29/2001	US20010047014 4-Benzyl-1-(2-(p-hydroxyphenoxy)ethyl)piperidine-3,4-diol; preparation from 1-(2-haloethoxy)-4-benzyloxybenzene and 4-benzylpiperidine-3,4-diol
11/29/2001	US20010047008 Allosteric adenosine receptor modulators
11/29/2001	US20010046993 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
11/29/2001	US20010046988 Especially treating fibromyalgia, chronic fatigue syndrome, psychogenic pain and chromic pain
11/29/2001	US20010046970 Inhibition of selectin binding
11/29/2001	US20010046963 Inhibiting cyclooxygenase-2 biosynthesis and Nuclear factor kappa B synthesis; treatment of arthritis and Alzheimer's disease; administering in food
11/29/2001	US20010046503 Reduction of adhesions using controlled delivery of active oxygen inhibitors
11/29/2001	US20010046483 Medicaments for manipulating T-cell immune response
11/29/2001	US20010046481 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
11/29/2001	EP1143949A3 19-nor-vitamin d3 compounds with calcemic activity
11/29/2001	DE10123349A1 New N-sulfonylated pipecolic acid derivatives, are matrix metalloprotease inhibitors useful e.g. for treating rheumatism, tumor progression, arteriosclerosis or inflammatory bowel disease
11/29/2001	DE10025558A1 Topische Zusammensetzung, enthaltend mindestens ein Aryloxim, und Verfahren zu ihrer Herstellung Topical composition comprising at least one aryl oxime, and processes for their preparation
11/29/2001	DE10025553A1 Zusammensetzung, enthaltend mindestens ein Aryloxim und mindestens einen Wirkstoff zur Behandlung von Akne und ihre Verwendung Composition containing at least one aryl oxime, and at least one active substance for the treatment of acne and their use
11/29/2001	CA2429199A1 Drug metabolizing enzymes
11/29/2001	CA2410593A1 Novel mmp-2/mmp-9 inhibitors
11/29/2001	CA2410294A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
11/29/2001	CA2410096A1 Card domain containing polypeptides, encoding nucleic acids, and methods of use
11/29/2001	CA2410004A1 Aerosol container for formulations of salmeterol xinafoate
11/29/2001	CA2409929A1 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
11/29/2001	CA2409868A1 Modulaton of alpha-6 integrin-mediated responses
11/29/2001	CA2409688A1 Method for improving the cell protection
11/29/2001	CA2409430A1 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
11/29/2001	CA2409367A1 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
11/29/2001	CA2409051A1 Antimigraine combination comprising sapindus and emblica extracts
11/29/2001	CA2408791A1 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation

1 ... 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 ... 1272